Compare Stocks: BIIB, ATAI, IXHL, NRXP, and ENVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
BIIB Biogen	$219.88 -1.3%	$215.32	$138.00 ▼ $230.49	$32.49B	0.09	1.20 million shs	774,023 shs
ENVB Enveric Biosciences	$1.48 +1.4%	$1.47	$1.17 ▼ $13.25	$6.63M	1.18	1.44 million shs	72,389 shs
IXHL Incannex Healthcare	$3.21 -1.2%	$3.30	$2.49 ▼ $15.00	$40.29M	6.97	307,779 shs	51,828 shs
NRXP NRx Pharmaceuticals	$2.90 +1.8%	$3.34	$1.62 ▼ $5.05	$125.57M	2.08	1.07 million shs	609,760 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	+0.14%	+41.62%	+41.35%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
ENVB Enveric Biosciences	-2.54%	-5.50%	+6.57%	+0.69%	-81.62%
IXHL Incannex Healthcare	+0.31%	-4.41%	+2.20%	-18.14%	-74.93%
NRXP NRx Pharmaceuticals	-2.40%	-5.94%	-17.15%	-26.36%	-14.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
BIIB Biogen	$219.88 -1.3%	$215.32	$138.00 ▼ $230.49	$32.49B	0.09	1.20 million shs	774,023 shs
ENVB Enveric Biosciences	$1.48 +1.4%	$1.47	$1.17 ▼ $13.25	$6.63M	1.18	1.44 million shs	72,389 shs
IXHL Incannex Healthcare	$3.21 -1.2%	$3.30	$2.49 ▼ $15.00	$40.29M	6.97	307,779 shs	51,828 shs
NRXP NRx Pharmaceuticals	$2.90 +1.8%	$3.34	$1.62 ▼ $5.05	$125.57M	2.08	1.07 million shs	609,760 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	+0.14%	+41.62%	+41.35%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
ENVB Enveric Biosciences	-2.54%	-5.50%	+6.57%	+0.69%	-81.62%
IXHL Incannex Healthcare	+0.31%	-4.41%	+2.20%	-18.14%	-74.93%
NRXP NRx Pharmaceuticals	-2.40%	-5.94%	-17.15%	-26.36%	-14.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	43.62% Upside
BIIB Biogen	2.56	Moderate Buy	$230.14	4.67% Upside
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
IXHL Incannex Healthcare	2.00	Hold	$18.00	460.75% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	1,089.66% Upside

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/22/2026	ATAI Atai Beckley	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/3/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$225.00 ➝ $245.00
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$240.00 ➝ $260.00
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	666.46	N/A	N/A	$0.69 per share	10.65
BIIB Biogen	$9.89B	3.28	$22.03 per share	9.98	$124.45 per share	1.77
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
IXHL Incannex Healthcare	$90K	447.62	N/A	N/A	$2.07 per share	1.55
NRXP NRx Pharmaceuticals	$1.23M	102.09	N/A	N/A	($0.54) per share	-5.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.92	13.65	2.49	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
ENVB Enveric Biosciences	-$8.77M	-$12.65	N/A	N/A	N/A	N/A	-168.04%	-145.95%	11/12/2026 (Estimated)
IXHL Incannex Healthcare	-$19.30M	-$1.69	N/A	N/A	N/A	N/A	-25.62%	-24.46%	11/13/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	BIIB Biogen	$2.03	N/A	N/A	N/A	$2.64 billion	N/A
9/25/2026	Q4 2026	IXHL Incannex Healthcare	$0.13	-$0.14	-$0.27	-$0.15	$0.20 million	N/A
8/14/2026	Q2 2026	ENVB Enveric Biosciences	N/A	-$0.76	N/A	-$0.76	N/A	N/A
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
BIIB Biogen	0.39	1.87	1.26
ENVB Enveric Biosciences	N/A	10.21	10.21
IXHL Incannex Healthcare	N/A	48.81	41.56
NRXP NRx Pharmaceuticals	N/A	0.86	0.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
BIIB Biogen	87.93%
ENVB Enveric Biosciences	13.82%
IXHL Incannex Healthcare	0.43%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
BIIB Biogen	0.25%
ENVB Enveric Biosciences	2.41%
IXHL Incannex Healthcare	1.33%
NRXP NRx Pharmaceuticals	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
ENVB Enveric Biosciences	6	4.48 million	4.37 million	Not Optionable
IXHL Incannex Healthcare	12	12.55 million	12.38 million	Not Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

Reviewing NRx Pharmaceuticals (NASDAQ:NRXP) and Elanco Animal Health (NYSE:ELAN)

October 1 at 5:14 AM | americanbankingnews.com

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for ...

September 30 at 7:50 AM | markets.businessinsider.com

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

September 30 at 7:00 AM | globenewswire.com

CASI Pharmaceuticals (NASDAQ:CASI) and NRx Pharmaceuticals (NASDAQ:NRXP) Head to Head Analysis

September 30 at 4:58 AM | americanbankingnews.com

Head to Head Contrast: BeOne Medicines (NASDAQ:ONC) and NRx Pharmaceuticals (NASDAQ:NRXP)

September 28, 2026 | americanbankingnews.com

Analyzing LENZ Therapeutics (NASDAQ:LENZ) & NRx Pharmaceuticals (NASDAQ:NRXP)

September 25, 2026 | americanbankingnews.com

NRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As Minor

September 16, 2026 | rttnews.com

NRx Pharmaceuticals Announces FDA Reclassification of ANDA Amendment for Preservative-Free Ketamine, Revises GDUFA Goal Date to November 10, 2026

September 15, 2026 | quiverquant.comQ

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

September 15, 2026 | globenewswire.com

European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP

September 14, 2026 | financialcontent.comF

NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at BTIG Research

September 14, 2026 | marketbeat.com

GeNeuro Secures European Patent For GNK-301 In ALS

September 14, 2026 | rttnews.com

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry

September 14, 2026 | seekingalpha.com

GeNeuro Announces European Patent for GNK-301, an Anti-HERV K Antibody for ALS, and Plans for Phase I Trials

September 14, 2026 | quiverquant.comQ

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

September 14, 2026 | globenewswire.com

FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)

September 11, 2026 | financialcontent.comF

NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System

September 11, 2026 | finance.yahoo.com

NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026 | finanznachrichten.de

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026 | globenewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of "Hold" by Analysts

September 9, 2026 | marketbeat.com

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

September 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Biogen NASDAQ:BIIB

$219.88 -2.94 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$220.60 +0.72 (+0.33%)

As of 05:01 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Enveric Biosciences NASDAQ:ENVB

$1.48 +0.02 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 +0.00 (+0.27%)

As of 04:59 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Incannex Healthcare NASDAQ:IXHL

$3.21 -0.04 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$3.24 +0.03 (+0.87%)

As of 04:51 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

NRx Pharmaceuticals NASDAQ:NRXP

$2.90 +0.05 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.04 (+1.21%)

As of 04:49 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

Biogen NASDAQ:BIIB

Enveric Biosciences NASDAQ:ENVB

Incannex Healthcare NASDAQ:IXHL

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

Biogen NASDAQ:BIIB

Enveric Biosciences NASDAQ:ENVB

Incannex Healthcare NASDAQ:IXHL

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools